Video

Dr. Gonzalez-Junca on Combining IL-21 and IL-15 in NK-Cell Therapy

Alba Gonzalez-Junca, PhD, discusses combining IL-21 and IL-15 cytokines in NK-cell thearpy.

Alba Gonzalez-Junca, PhD, associate director, senior scientist, Cancer Immunotherapy, Senti Biosciences, discusses combining IL-21 and IL-15 cytokines in NK-cell thearpy.

There is previous data in the CAR T-cell space demonstrating advantages of combining IL-21 and IL-15 cytokines, though this has not been shown on NK cells, Gonzalez-Junca says. The use of IL-21 alone did not generate much activity with NK cells, based on screening results, Gonzalez-Junca adds. IL-15 increased the killing compared with CAR T-cell therapy alone, and the combination of IL-15 and IL-21 demonstrated the ability to control the tumor in vitro, Gonzalez-Junca explains.

Further research into the calibrated release of IL-15 and IL-21 is ongoing, Gonzalez-Junca continues. In addition to IL-21 and IL-15, other cytokines, such as IL-7, are being explored to examine if they can elicit similar activity, Gonzalez-Junca concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity
Proactive Adverse Event Management for HER2+ BTC Treatments
Video

Proactive Adverse Event Management for HER2+ BTC Treatments

May 8th 2025 - May 9th 2026

online-activity
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina
Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

May 2nd 2025 - Jun 7th 2025

online-activity